Key Takeaways
- Biotech and laboratory businesses on AOS EAD qualify using SSN + EIN + 3 months of contract research or testing revenue bank statements
- CLIA-certified labs, CROs, and biotech product companies with commercial revenue are all eligible for Bankable funding
- SBA loans now require 100% US citizen ownership (March 2026) — biotech firms on AOS must rely on private capital alternatives
- Lab equipment, reagent inventory, quality systems, and research staff hiring are primary capital uses in this sector
- Biotech businesses with $25K+ in monthly contract or product revenue and 6+ months of commercial activity qualify for our program
The United States biotechnology and laboratory services sector has been built substantially on the contributions of immigrant scientists, researchers, and entrepreneurs. From genomics to diagnostics to biomanufacturing, many of the most innovative commercial biotech businesses were founded or are owned by scientists who came to the United States on H-1B, O-1, or J-1 exchange visas, built their scientific credentials at major research institutions, and launched commercial ventures. A significant number hold AOS EAD status.
Biotech businesses that have crossed the commercialization threshold — meaning they generate documented revenue from testing services, contract research, reagent sales, licensing agreements, or biotech product sales — are strong candidates for Bankable's revenue-based funding program. We distinguish commercial biotech (revenue-generating) from purely pre-revenue research ventures. Commercial biotech operations with SSN, EIN, and bank deposit history qualify for our program regardless of immigration status.
Capital Uses for Biotech and Laboratory Businesses
Laboratory Equipment Acquisition and Upgrade
Analytical instruments — mass spectrometers ($50K–$500K), PCR systems ($5K–$50K), flow cytometers ($30K–$300K), liquid handling robots ($30K–$200K), and biosafety cabinets ($3K–$20K) — are the capital backbone of laboratory operations. Revenue-based advances from Bankable fund equipment acquisitions that expand testing and research capacity, bypassing SBA citizenship requirements.
Reagent and Consumable Inventory
Laboratory reagents, assay kits, media, buffers, and consumables represent significant monthly operating costs — often $10K–$100K for a mid-size commercial lab. Pre-purchasing reagents at favorable pricing (e.g., before a supplier's announced price increase) or maintaining strategic inventory to prevent supply disruptions requires working capital that revenue-based advances can provide.
CLIA Certification and Regulatory Compliance
Clinical laboratories require CLIA certification from CMS, CAP accreditation, and state laboratory licensing. For clinical testing labs, FDA oversight of laboratory-developed tests adds additional compliance infrastructure costs. Regulatory compliance investment for a new clinical test or expanded test menu can run $20K–$200K. Working capital advances fund compliance investments that unlock new testing revenue.
Scientific Staff Hiring
Laboratory scientists, clinical laboratory directors, quality assurance specialists, and regulatory affairs managers are expensive and difficult to recruit. Annual compensation for a laboratory director runs $120K–$220K. Revenue-based advances fund critical hires that expand laboratory capacity and service menu.
| Factor | Bankable Standard |
|---|---|
| Immigration Status | AOS EAD or parolee-in-place EAD |
| Revenue Stage | Commercial (revenue-generating) — not pre-revenue research |
| Monthly Revenue | $25,000+ in testing/contract/product revenue |
| Business History | 6 months minimum commercial operations |
| Documentation | SSN + EIN + 3 months bank statements |
| Funding Available | $50,000 to $5,000,000 |
| Decision Timeline | 48 hours from complete application |
Commercial biotech businesses at the revenue-generating stage with consistent bank deposits are strong Bankable candidates. Check your Bankability Score for personalized options.
Frequently Asked Questions
Yes, if your biotech business is revenue-generating. We provide revenue-based advances for CLIA labs, CROs, reagent manufacturers, and other commercial biotech operations owned by AOS EAD holders. No green card required.
No. We look at revenue (gross deposits), not profitability. Many biotech companies are revenue-positive but not yet profitable due to R&D investment. Revenue-based advances are structured against gross revenue deposits.
Yes. Laboratory equipment purchases are the most common capital use for biotech businesses. We advance against commercial testing or product revenue to fund equipment acquisitions that expand analytical capacity.
CLIA certification is a positive indicator that your clinical laboratory operates under federal quality standards. Certified labs with established test menus and consistent physician or hospital client billing are strong Bankable candidates.
Yes. CROs with documented sponsor study contracts and milestone billing qualify. We look at revenue deposits from pharmaceutical or biotech sponsor payments. Large, variable contract payments (milestone billing) are handled by looking at 12-month annualized revenue.
SBA loans require 100% US citizen ownership. Biotech business owners on AOS EAD — even those with PhD credentials, published research, and commercial revenue — are excluded from all SBA programs. Bankable provides private capital with no citizenship requirement.
Yes. CLIA verification studies, FDA submission preparation, and quality system upgrades for new tests are valid working capital uses. We advance against existing test menu revenue to fund expansion into new testing capabilities.
Up to $5 million based on documented commercial revenue. A clinical lab with $200K in monthly testing revenue could qualify for $400K–$800K. Commercial biotech product companies with distributor revenue can access larger amounts.